Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$5.91
-0.05 (-0.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $14.6M · quality 30.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.4B
P/E
42.2x
↑EV/EBITDA
23.1x
↑ROE
8.6%
↑Gross Margin
33.1%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.7%
FCF CAGR
—
FCF margin
7.4%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $323.1M · net income $96.3M · FCF $23.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $323.1M | $323.1M | $405.2M | $420.6M | $373.4M |
| Net Income | $96.3M | $96.3M | $34.2M | $-11.9M | $-132.7M |
| EBITDA | $162.7M | $162.7M | $102.0M | $74.6M | $-41.4M |
| EPS | 0.13 | 0.13 | 0.05 | -0.02 | -0.25 |
| Gross Margin | 33.1% | 33.1% | 31.2% | 32.1% | 35.8% |
| Operating Margin | -3.8% | -3.8% | -0.5% | -6.2% | -2.5% |
| Net Margin | 29.8% | 29.8% | 8.5% | -2.8% | -35.5% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.34 | 1.19 | 3.16 |
| Current Ratio | 7.91 | 7.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $23.8M | $23.8M | $14.6M | $7.2M | $-9.1M |
| Returns | |||||
| ROE | 8.6% | 8.6% | 3.5% | -2.0% | -44.0% |
| Valuation | |||||
| P/E | 42.21 | 42.21 | 57.40 | — | — |
| EV/EBITDA | 23.10 | 23.10 | 15.23 | 33.26 | — |
| P/B | 3.91 | 3.91 | 2.02 | 4.32 | 8.77 |
| Growth & Yield | |||||
| Revenue Growth | -20.2% | -20.2% | -3.7% | 12.6% | — |
| EPS Growth | 160.0% | 160.0% | 350.0% | 92.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
59.2%
EPS terminal req.
$0.52
Spread vs growth
100.8%
5Y implied EPS CAGR
37.3%
EPS terminal req.
$0.63
Spread vs growth
122.7%
10Y implied EPS CAGR
22.9%
EPS terminal req.
$1.02
Spread vs growth
137.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+71.3%
Start / end P/E
69.0x → 45.5x
EPS bridge
0.05 → 0.13
Residual
-54.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.